• Minicabecera4


Histocell SPINE

Histocell and the pharmaceutical company Ferrer today announced that the first patients have been recruited for a Phase 1/2 clinical trial of FAB117-HC, a new cell therapy medicinal product for the treatment of acute spinal cord injuries of traumatic origin.

It is the first cellular medication designed to treat acute traumatic spinal cord injury, in the first 2-3 days after the accident, that has reached the clinical regulatory phase.

SPINE (Spinal acute Injury Neurosave Evaluation) is a Phase 1/2 clinical trial that evaluates the safety and preliminary efficacy of the drug in a total of 46 adult patients with acute traumatic spinal cord injury.



In order to promote Reoxcare, innovative product for wound healing, Histocell attended last February in Madrid, the 7th Congress organized by SEHER, Spanish Society of Wounds.

At our stand, we had the opportunity to welcome all those interested in knowing the advantages of using our novel dressing for wound healing and to show success cases of patients with chronic wounds that improved satisfactorily thanks to the antioxidant properties of Reoxcare®.



The use of an antioxidant dressing on hard-to-heal wounds: a multicentre, prospective case series

Read the complete article at:


or get in touch with us for more information.


Reoxcare supports the publication of the Wound Care special issue of Health Awareness distributed with The Guardian December 12th.

If you didn't have the opportunity to have a copy of December 12th The Guardian, click the link below to read the complete issue about Wound Care published by MediaPlanet UK.

Being wound care awareness one of the main objetives of Histocell and our product Reoxcare, we didn't want to miss the opportunity to take part in this supplement that tries to make public the need to consider wound care as a top issue in nowadays health systems.

As we can read in the following article signed by Professor Sue Bale, President-Elect of the EWMA, wounds can dictate a patients life and there are more than two million people each year suffering them. The need for dedicated care by specialists that know the best way to approach each wound is essential.

Read article by Proffesor Sue Bale.

Read the whole publication.